---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-000084"
form_type: "8-K"
ticker: "NMRA"
cik: "0001885522"
company_name: "Neumora Therapeutics, Inc."
filed_at: "2025-01-02T23:59:59+00:00"
generated_at: "2026-05-28T18:59:16.805533+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Neumora's Phase 3 KOASTAL-1 study of navacaprant fails primary endpoint in MDD

## Summary
- Primary endpoint MADRS total score change at Week 6: -12.5 for both navacaprant and placebo (p=0.993); no statistical improvement.
- Key secondary endpoint SHAPS also missed: -5.8 vs -5.5 (p=0.648).
- Pre-specified subgroup analysis showed efficacy signal in females: MADRS LSMD -2.7 (p=0.072); SHAPS LSMD -2.3 (p=0.015).
- Navacaprant generally well-tolerated; no serious adverse events; discontinuation 2.1% vs 3.1% for placebo.
- Cash balance $342M provides runway into mid-2026; J.P. Morgan Healthcare Conference update planned Jan 14.

## SEC filing metadata
- accession: 0001193125-25-000084
- form_type: 8-K
- ticker: NMRA
- cik: 0001885522
- company_name: Neumora Therapeutics, Inc.
- filed_at: 2025-01-02T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1885522/000119312525000084/0001193125-25-000084-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1885522/000119312525000084/d859264d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-000084
- JSON: https://secwatch.observer/filing/0001193125-25-000084.json
- Plain text: https://secwatch.observer/filing/0001193125-25-000084.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.